Brazil approves first domestic BCI clinical trial under new ANVISA neurotechnology framework

Summary

Brazil's ANVISA health regulator approved the country's first domestic BCI clinical trial — a 20-patient study of an EEG-based communication device for ALS patients developed by the Federal University of São Paulo. The trial marks a milestone for Latin American neurotech and comes under a new ANVISA framework specifically for neural interface devices.